Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123030) titled 'Precision Sedation for Airway Safety: Model Development and Validation of Remimazolam Besylate in Obese Patients Undergoing Painless Gastrointestinal Endoscopy' on April 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Baoji High-Tech Hospital
Condition:
None
Intervention:
Pre-study - Normal Weight Group:Intravenous bolus of remimazolam besylate was administered at an initial dose of 0.15 mg/kg. The dose for the next patient was determined using the modified Dixon sequential method based on the sedation response of the previous patient, with an adjacent dose ratio of 1.2. Remifent...